search
Back to results

Clinical Assessment of Complementary Treatment With Qishen Yiqi Dripping Pills on Ischemic Heart Failure (CACT-IHF)

Primary Purpose

Ischemic Heart Failure

Status
Unknown status
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Qishen Yiqi Dripping Pills
Qishen Yiqi dripping pills dummy
Sponsored by
State Administration of Traditional Chinese Medicine of the People's Republic of China
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Ischemic Heart Failure

Eligibility Criteria

40 Years - 79 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age 40 to 79

  • Patients with ischemic heart failure：

    • LVEF less than or equal to 45% measured by echocardiography in modified Simpson method
    • History of prior myocardial infarction with or without percutaneous coronary intervention (PCI) or/and coronary artery bypass grafting (CABG);
    • Coronary angiography (CAG) or coronary CTA shows more than or equal to 50% stenosis in at least one of the main coronary arteries with or without revascularization, of which the researcher thinks that it is closely related to heart failure;
    • With or without dyspnea, fatigue and fluid retention (edema) etc.
  • History of heart failure or present with heart failure symptoms for at least 3 months;
  • New York Heart Association (NYHA) Class II to IV;
  • Submitted informed consent

Exclusion Criteria:

  • Acute heart failure or acute exacerbation of chronic heart failure

  • Those who have one of the following diseases:

    • Acute coronary syndrome within 30 days
    • Revascularization therapy within 6 months
    • Uncontrolled hypertension with systolic pressure more than or equal to 180mmHg and/or diastolic pressure more than or equal to 110mmHg
    • Second degree type 2 or worse sinoatrial/atrioventricular block without implantation of pacemaker or uncontrolled malignant cardiac arrhythmia
    • Dilated cardiomyopathy
    • Hypertrophic obstructive cardiomyopathy
    • Myocarditis
    • Pulmonary artery embolism
    • Severe valvular heart disease
    • Pulmonary heart disease
    • Stroke within 6 months
  • Cardiac resynchronization therapy
  • Applied diuretics, cardiotonic agents or vasodilators intravenously within 7 days
  • Severe endocrine diseases such as hyperthyroidism, etc.
  • History of malignant tumor
  • Hemoglobin (HB )≤ 9g/dl
  • Alanine aminotransferase (ALT) > 2 times the upper limit of normal
  • Serum creatinine > 265 μmol/L
  • Mental disorder
  • Being pregnant, planning for pregnancy or breastfeeding
  • Suspicious or definite allergy to intervention drugs
  • Participated in other trials within 2 months
  • Unable to walk autonomously due to physical disabilities

Sites / Locations

  • Beijing Hospital of Traditional Chinese MedicineRecruiting
  • Fuwai HospitalRecruiting
  • Xiyuan Hospital of China Academy of Chinese Medical SciencesRecruiting
  • Guangdong Provincial Hospital of TCMRecruiting
  • Second Affiliated Hospital of TCM College GuiyangRecruiting
  • 252 Hospital of Chinese People's Liberation ArmyRecruiting
  • The 1st Affiliated Hospital of Heilongjiang Traditional Chinese Medicine UniversityRecruiting
  • The First Affiliated Hospital of Henan University of TCMRecruiting
  • The Affiliated Nanhua Hospital of Nanhua UniversityRecruiting
  • Jiangsu Province Traditional Chinese Medicine HospitalRecruiting
  • Nanjing Hospital of T.C.MRecruiting
  • The Affiliated Hospital of Jiangxi University of TCMRecruiting
  • The Affiliated Hospital To Changchun University of Chinese MedicineRecruiting
  • The First Hospital of Jilin UniversityRecruiting
  • Affiliated Hospital of Liaoning University of Traditional Chinese MedicineRecruiting
  • Shengjing Hospital of China Medical UniversityRecruiting
  • The First Hospital of China Medical UniversityRecruiting
  • The Second Affiliated Hospital of Liaoning University of Traditional Chinese MedicineRecruiting
  • Second Affiliated Hospital of Shaanxi University of Chinese MedicineRecruiting
  • Shandong Province Traditional Chinese Medicine University Affiliated HospitalRecruiting
  • Ruijin Hospital Affiliated to The Shanghai Jiao Tong University Medical SchoolRecruiting
  • Shanghai Shuguang HospitalRecruiting
  • Traditional Chinese Medicine Hospital of Shan Xi ProvinceRecruiting
  • Teaching Hospital of Chengdu University of TCMRecruiting
  • Affiliated Hospital of Medical College of Chinese People's Armed Police ForcesRecruiting
  • First Teaching Hospital of Tianjin University of Traditional Chinese MedicineRecruiting
  • Second Affiliated Hospital of Tianjin University of TCMRecruiting
  • The 2nd Hospital of Tianjin Medical UniversityRecruiting
  • Tian Jin Chest HospitalRecruiting
  • Tianjin Academy of Traditional Chinese Medicine Affliated HospitalRecruiting
  • Traditional Chinese Medical Hospital of Xinjiang Uyghur Autonomous RegionRecruiting
  • The First Affiliated Hospital of Anhui University of TCMRecruiting
  • Dong Fang HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Experimental

Arm Label

Qishen Yiqi dripping pills dummy

Qishen Yiqi Dripping Pills

Arm Description

Outcomes

Primary Outcome Measures

6MWT distance
6MWT
6MWT

Secondary Outcome Measures

Composite endpoint
all-cause death, frequency of emergency/re-admission to hospital due to HF, frequency of re-admission due to cardiovascular disease, acute coronary syndrome, severe arrhythmia, cardiac shock, revascularization, stroke, pulmonary embolism and peripheral vascular incidences, etc.
Brain natriuretic peptide (BNP)
Echocardiography
Cardiothoracic Ratio(CR)
Cardiac function classification, NYHA
Minnesota life quality scale
Scores from the four TCM diagnostic methods
blood and urine routine tests,liver and renal function tests,serum electrolytes,electrocardiogram (ECG)

Full Information

First Posted
February 29, 2012
Last Updated
March 19, 2013
Sponsor
State Administration of Traditional Chinese Medicine of the People's Republic of China
search

1. Study Identification

Unique Protocol Identification Number
NCT01555320
Brief Title
Clinical Assessment of Complementary Treatment With Qishen Yiqi Dripping Pills on Ischemic Heart Failure
Acronym
CACT-IHF
Official Title
Clinical Assessment of Complementary Treatment With Qishen Yiqi Dripping Pills on Ischemic Heart Failure (CACT-IHF) A Randomized, Double-blind, Multicenter, Placebo-controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
March 2013
Overall Recruitment Status
Unknown status
Study Start Date
March 2012 (undefined)
Primary Completion Date
September 2013 (Anticipated)
Study Completion Date
December 2013 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
State Administration of Traditional Chinese Medicine of the People's Republic of China

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
CACT-IHF aims to evaluate the clinical efficacy and safety of Qishen Yiqi Dripping Pills in treating ischemic heart failure. Meeting the diagnosis, inclusion and exclusion criteria, the study plans to recruit 640 cases from 35 upper class hospitals in China, who are divided into two groups (treatment and control group) by central randomization service. The treatment group will be administrated with one bag of Qishen Yiqi Dripping Pills (0.52g/bag) three times a day in addition to standardized western medications. Whereas the control group will be given one bag of Qishen Yiqi Dripping Pills dummy (0.52g/bag) three times a day in addition to standardized western medications. Efficacy indicators include primary indicator (6 minute walk test) and secondary indicators: composite endpoint consisting of all-cause death, emergency/re-admission to hospital due to HF, frequency of re-admission due to cardiovascular disease, acute coronary syndrome, severe arrhythmia, cardiac shock, revascularization, stroke, pulmonary embolism and peripheral vascular incidences, etc.; Brain Natriuretic Peptide; echocardiography; cardiothoracic ratio; NYHA cardiac function classification; Minnesota life quality scale; scores from the four traditional chinese medicine (TCM) diagnostic methods). Other indicators include blood cholesterol, triglyceride, high density cholesterol and low density cholesterol. Safety indicators include blood pressure, heart rate, blood and urine routine tests, liver and renal function tests, serum electrolytes, electrocardiogram and adverse events. All of the patients will receive interventional drug treatment for 6 months. Follow up is needed on the 1st, 3rd, 6th, 9th, 12th month after recruitment. All patients will be followed up until the end of study (Refers to the 12th month of the last case recruited into the study).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ischemic Heart Failure

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
640 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Qishen Yiqi dripping pills dummy
Arm Type
Placebo Comparator
Arm Title
Qishen Yiqi Dripping Pills
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Qishen Yiqi Dripping Pills
Intervention Description
One packet of Qishen Yiqi Dripping Pills (0.52g) will be given three times a day in addition to regular western medications for the first 6 months, and regular western medications only for the subsequent 6 months.
Intervention Type
Drug
Intervention Name(s)
Qishen Yiqi dripping pills dummy
Intervention Description
One packet of Qishen Yiqi Dripping Pills dummy (0.52g) will be given three times a day in addition to regular western medications for the first 6 months, and regular western medications only for the subsequent 6 months.
Primary Outcome Measure Information:
Title
6MWT distance
Time Frame
0 month
Title
6MWT
Time Frame
3rd month
Title
6MWT
Time Frame
6th month
Secondary Outcome Measure Information:
Title
Composite endpoint
Description
all-cause death, frequency of emergency/re-admission to hospital due to HF, frequency of re-admission due to cardiovascular disease, acute coronary syndrome, severe arrhythmia, cardiac shock, revascularization, stroke, pulmonary embolism and peripheral vascular incidences, etc.
Time Frame
1st,3rd,6th,9th,12th month
Title
Brain natriuretic peptide (BNP)
Time Frame
0,6th month
Title
Echocardiography
Time Frame
0,6th month
Title
Cardiothoracic Ratio(CR)
Time Frame
0,6th month
Title
Cardiac function classification, NYHA
Time Frame
0,1st,3rd,6th,9th,12th month
Title
Minnesota life quality scale
Time Frame
0,1st,3rd,6th,9th,12th month
Title
Scores from the four TCM diagnostic methods
Time Frame
0,1st,3rd,6th,9th,12th month
Title
blood and urine routine tests,liver and renal function tests,serum electrolytes,electrocardiogram (ECG)
Time Frame
0,3rd,6thmonth

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
79 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 40 to 79 Patients with ischemic heart failure： LVEF less than or equal to 45% measured by echocardiography in modified Simpson method History of prior myocardial infarction with or without percutaneous coronary intervention (PCI) or/and coronary artery bypass grafting (CABG); Coronary angiography (CAG) or coronary CTA shows more than or equal to 50% stenosis in at least one of the main coronary arteries with or without revascularization, of which the researcher thinks that it is closely related to heart failure; With or without dyspnea, fatigue and fluid retention (edema) etc. History of heart failure or present with heart failure symptoms for at least 3 months; New York Heart Association (NYHA) Class II to IV; Submitted informed consent Exclusion Criteria: Acute heart failure or acute exacerbation of chronic heart failure Those who have one of the following diseases: Acute coronary syndrome within 30 days Revascularization therapy within 6 months Uncontrolled hypertension with systolic pressure more than or equal to 180mmHg and/or diastolic pressure more than or equal to 110mmHg Second degree type 2 or worse sinoatrial/atrioventricular block without implantation of pacemaker or uncontrolled malignant cardiac arrhythmia Dilated cardiomyopathy Hypertrophic obstructive cardiomyopathy Myocarditis Pulmonary artery embolism Severe valvular heart disease Pulmonary heart disease Stroke within 6 months Cardiac resynchronization therapy Applied diuretics, cardiotonic agents or vasodilators intravenously within 7 days Severe endocrine diseases such as hyperthyroidism, etc. History of malignant tumor Hemoglobin (HB )≤ 9g/dl Alanine aminotransferase (ALT) > 2 times the upper limit of normal Serum creatinine > 265 μmol/L Mental disorder Being pregnant, planning for pregnancy or breastfeeding Suspicious or definite allergy to intervention drugs Participated in other trials within 2 months Unable to walk autonomously due to physical disabilities
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Yazhu Hou, Dr.
Phone
8622-27432325
Email
mreleven@163.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jingyuan Mao, Dr.
Organizational Affiliation
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Beijing Hospital of Traditional Chinese Medicine
City
Beijing
State/Province
Beijing
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yao Han, Dr.
Email
Hanyao1212@126.com
First Name & Middle Initial & Last Name & Degree
Hongxu Liu, Prof
Facility Name
Fuwai Hospital
City
Beijing
State/Province
Beijing
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bingqi Wei, Dr.
Email
weibing918q@sina.com
First Name & Middle Initial & Last Name & Degree
Jian Zhang, Prof
Facility Name
Xiyuan Hospital of China Academy of Chinese Medical Sciences
City
Beijing
State/Province
Beijing
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yang Miao, Dr.
Email
Miya9@163.com
First Name & Middle Initial & Last Name & Degree
Yang Miao, Dr.
Facility Name
Guangdong Provincial Hospital of TCM
City
Guangdong
State/Province
Guangdong
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xiaogang Sheng, Dr.
Email
shengxiaogang1@sina.com.cn
First Name & Middle Initial & Last Name & Degree
Huanlin Wu, Prof
Facility Name
Second Affiliated Hospital of TCM College Guiyang
City
Guiyang
State/Province
Guizhou
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tingchun Wu, Dr.
Email
649164263@qq.com
First Name & Middle Initial & Last Name & Degree
Tao Xu, Dr.
Facility Name
252 Hospital of Chinese People's Liberation Army
City
Baoding
State/Province
Hebei
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xuebin Cao, Dr.
Email
cxb13633227588@126.com
First Name & Middle Initial & Last Name & Degree
Xuebin Cao, Dr.
Facility Name
The 1st Affiliated Hospital of Heilongjiang Traditional Chinese Medicine University
City
Heilongjiang
State/Province
Heilongjiang
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yan Wang, Dr.
Email
19911737@qq.com
First Name & Middle Initial & Last Name & Degree
Yang Li, Dr.
Email
19911737@qq.com
First Name & Middle Initial & Last Name & Degree
Yabin Zhou, Prof
Facility Name
The First Affiliated Hospital of Henan University of TCM
City
Zhengzhou
State/Province
Henan
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tinghai Du, Dr.
Email
dth2010@163.com
First Name & Middle Initial & Last Name & Degree
Mingjun Zhu, Dr.
Facility Name
The Affiliated Nanhua Hospital of Nanhua University
City
Hengyang
State/Province
Hunan
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Huan Liu, Dr.
First Name & Middle Initial & Last Name & Degree
Xiaofeng Ma, Dr.
Facility Name
Jiangsu Province Traditional Chinese Medicine Hospital
City
Nanjing
State/Province
Jiangsu
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bo Zhu, Dr.
Email
najahannah@sina.com
First Name & Middle Initial & Last Name & Degree
Xiaohu Chen, Dr.
Facility Name
Nanjing Hospital of T.C.M
City
Nanjing
State/Province
Jiangsu
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zhongxing Shao, Dr.
Email
Szx790102@sohu.com
First Name & Middle Initial & Last Name & Degree
Ning Gu, Dr.
Facility Name
The Affiliated Hospital of Jiangxi University of TCM
City
Nanchang
State/Province
Jiangxi
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Peng Deng, Dr.
Email
dengpeng615@sina.com
First Name & Middle Initial & Last Name & Degree
Zhongyong Liu, Dr.
Facility Name
The Affiliated Hospital To Changchun University of Chinese Medicine
City
Changchun
State/Province
Jilin
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yudan Tian, Dr.
Email
30880356@qq.com
First Name & Middle Initial & Last Name & Degree
Yue Deng, Dr.
Facility Name
The First Hospital of Jilin University
City
Changchun
State/Province
Jilin
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yaqiu Jiang, Dr.
Email
yaqiujiang@163.com
First Name & Middle Initial & Last Name & Degree
Yaqiu Jiang, Dr.
Facility Name
Affiliated Hospital of Liaoning University of Traditional Chinese Medicine
City
Shenyang
State/Province
Liaoning
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ying Yang, Dr.
Email
Yang_ying_2002@sina.com
First Name & Middle Initial & Last Name & Degree
Fengrong Wang, Dr.
Facility Name
Shengjing Hospital of China Medical University
City
Shenyang
State/Province
Liaoning
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tao Ding, Dr.
Email
chensn@sj-hospital.org
First Name & Middle Initial & Last Name & Degree
Suning Chen, Prof
Facility Name
The First Hospital of China Medical University
City
Shenyang
State/Province
Liaoning
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Haiyan Shan, Dr.
Email
shanhy024@163.com
First Name & Middle Initial & Last Name & Degree
Xiaojuan Bai, Dr.
Facility Name
The Second Affiliated Hospital of Liaoning University of Traditional Chinese Medicine
City
Shenyang
State/Province
Liaoning
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Donghai Wang, Dr.
Email
fine_dongbo@163.com
First Name & Middle Initial & Last Name & Degree
Bo Dong, Dr.
Facility Name
Second Affiliated Hospital of Shaanxi University of Chinese Medicine
City
Xianyang
State/Province
Shaanxi
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jing Qi
Email
404317104@qq.com
First Name & Middle Initial & Last Name & Degree
Yonggang Wang, Dr.
Facility Name
Shandong Province Traditional Chinese Medicine University Affiliated Hospital
City
Shandong
State/Province
Shandong
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yunlun Li, Dr.
Email
liyunlun@163.com
First Name & Middle Initial & Last Name & Degree
Yitao Xue
Facility Name
Ruijin Hospital Affiliated to The Shanghai Jiao Tong University Medical School
City
Shanghai
State/Province
Shanghai
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Qingfen Zhou, Dr.
Email
zhouqingfen@hotmail.com
First Name & Middle Initial & Last Name & Degree
Fengru Zhang, Dr.
Facility Name
Shanghai Shuguang Hospital
City
Shanghai
State/Province
Shanghai
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yongming Liu, Dr.
Email
liuyongming@foxmail.com
First Name & Middle Initial & Last Name & Degree
Xiaolong Wang, Dr.
Facility Name
Traditional Chinese Medicine Hospital of Shan Xi Province
City
Taiyuan
State/Province
Shanxi
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tianfu Niu, Dr.
Email
niutianfu2584@sina.com
First Name & Middle Initial & Last Name & Degree
Tianfu Niu, Dr.
Facility Name
Teaching Hospital of Chengdu University of TCM
City
Chengdu
State/Province
Sichuan
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Li Jiang, Dr.
Email
cdwwx729@163.com
First Name & Middle Initial & Last Name & Degree
Weixing Wang, Dr.
Facility Name
Affiliated Hospital of Medical College of Chinese People's Armed Police Forces
City
Tianjin
State/Province
Tianjin
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jun Tian, Dr.
Email
Tianjun6666@hotmail.com
First Name & Middle Initial & Last Name & Degree
Tiemin Jiang, Dr.
Facility Name
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
City
Tianjin
State/Province
Tianjin
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yazhu Hou
Email
mreleven@163.com
First Name & Middle Initial & Last Name & Degree
Jingyuan Mao, Dr.
Facility Name
Second Affiliated Hospital of Tianjin University of TCM
City
Tianjin
State/Province
Tianjin
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tao Wang, Dr.
Email
Wangtao973@163.com
First Name & Middle Initial & Last Name & Degree
Yingqiang Zhao, Dr.
Facility Name
The 2nd Hospital of Tianjin Medical University
City
Tianjin
State/Province
Tianjin
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ruyu Yuan, Dr.
Email
tjcardio@gmail.com
First Name & Middle Initial & Last Name & Degree
Ruyu Yuan, Dr.
Facility Name
Tian Jin Chest Hospital
City
Tianjin
State/Province
Tianjin
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jie Geng, Dr.
Email
gengjie_1973@126.com
First Name & Middle Initial & Last Name & Degree
Shutao Chen, Dr.
Facility Name
Tianjin Academy of Traditional Chinese Medicine Affliated Hospital
City
Tianjin
State/Province
Tianjin
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Chuanhui Huang, Dr.
Email
huangchuanhui66@sina.com
First Name & Middle Initial & Last Name & Degree
Ruihong Fan, Dr.
Facility Name
Traditional Chinese Medical Hospital of Xinjiang Uyghur Autonomous Region
City
Urumqi
State/Province
Xinjiang
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dongqing An, Dr.
Email
wxf87112008@163.com
First Name & Middle Initial & Last Name & Degree
Xiaofeng Wang, Dr.
Facility Name
The First Affiliated Hospital of Anhui University of TCM
City
Anhui
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zhengbin Shao, Dr.
Email
shaozhengbin@126.com
First Name & Middle Initial & Last Name & Degree
Xiaohua Dai, Dr.
Facility Name
Dong Fang Hospital
City
Beijing
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jinjin Lu, Dr.
Email
Lu2008jinjin@126.com
First Name & Middle Initial & Last Name & Degree
Yang Wu, Dr.

12. IPD Sharing Statement

Citations:
PubMed Identifier
23672353
Citation
Hou YZ, Wang S, Zhao ZQ, Wang XL, Li B, Soh SB, Mao JY. Clinical assessment of complementary treatment with Qishen Yiqi dripping pills on ischemic heart failure: study protocol for a randomized, double-blind, multicenter, placebo-controlled trial (CACT-IHF). Trials. 2013 May 14;14:138. doi: 10.1186/1745-6215-14-138.
Results Reference
derived

Learn more about this trial

Clinical Assessment of Complementary Treatment With Qishen Yiqi Dripping Pills on Ischemic Heart Failure

We'll reach out to this number within 24 hrs